Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Aug;56(4):646-663.
doi: 10.1111/apt.17055. Epub 2022 Jun 20.

A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre

Susanna Meade  1 , Kamal V Patel  2 , Raphael P Luber  1 , Dearbhaile O'Hanlon  3 , Andra Caracostea  1 , Polychronis Pavlidis  4 , Sailish Honap  1 , Cheran Anandarajah  1 , Nyree Griffin  5 , Sebastian Zeki  1 , Shuvra Ray  1 , Joel Mawdsley  1 , Mark A Samaan  1 , Simon H Anderson  1 , Amir Darakhshan  6 , Katie Adams  6 , Andrew Williams  6 , Jeremy D Sanderson  1 , Miranda Lomer  3 , Peter M Irving  1   4
Affiliations
Observational Study

A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre

Susanna Meade et al. Aliment Pharmacol Ther. 2022 Aug.

Abstract

Background: Low-quality evidence suggests that pre-operative exclusive enteral nutrition (E/EN) can improve postoperative outcomes in patients with Crohn's disease (CD). It is not standard practice in most centres.

Aims: To test the hypothesis that pre-operative EN in patients undergoing ileal/ileocolonic surgery for CD is associated with improved postoperative outcome.

Methods: We performed a single centre retrospective observational study comparing surgical outcomes in patients receiving pre-operative EN (≥600 kcal/day for ≥2 weeks) with those who received no nutritional optimisation. Consecutive adult patients undergoing ileal/ileocolonic resection from 2008 to 2020 were included. The primary outcome was postoperative complications <30 days. Secondary outcomes included EN tolerance, specific surgical complications, unplanned stoma formation, length of stay, length of bowel resected, readmission and biochemical/anthropometric changes.

Results: 300 surgeries were included comprising 96 without nutritional optimisation and 204 optimised cases: oral EN n = 173, additional PN n = 31 (4 of whom had received nasogastric/nasojejunal EN). 142/204 (69.6%) tolerated EN. 125/204 (61.3%) initiated EN in clinic. Patients in the optimised cohort were younger at operation and diagnosis, with an increased frequency of penetrating disease and exposure to antibiotics or biologics, and were more likely to undergo laparoscopic surgery. The optimised cohort had favourable outcomes on multivariate analysis: all complications [OR 0.29; 0.15-0.57, p < 0.001], surgical complications [OR 0.41; 95% CI 0.20-0.87, p = 0.02], non-surgical complications [OR 0.24 95% CI 0.11-0.52, p < 0.001], infective complications [OR 0.32; 95% CI 0.16-0.66, p = 0.001].

Conclusions: Oral EN was reasonably well tolerated and associated with a reduction in 30-day postoperative complications. Randomised controlled trials are required to confirm these findings.

Keywords: Crohn’s disease; enteral nutrition; surgery.

PubMed Disclaimer

Conflict of interest statement

SM has received speaker fees from FalkPharma and an educational grant from Pfizer. KP has received honoraria for educational meetings and speaker fees from Abbvie, Janssen, Takeda, DrFalk, PredictImmune and Ferring. KP has received Advisory Board fees from Abbvie, Galapagos and Janssen. RPL has received educational grants from Ferring, Pfizer and Vifor Pharma. PMI: AbbVie, Celgene, Falk Pharma, Ferring MSD, Janssen, Pfizer, Takeda, Tillotts, Sandoz, Shire, Warner Chilcott ‐ Speaking/education, intermittent (last 3 years). SH has received lecture fees from Pfizer, Janssen and Takeda. DOH, AC, PP, CA, NG, SZ, SR, JM, MAS, SHA, KA, AD, AW, JDS, ML none declared.

Figures

FIGURE 1
FIGURE 1
Patient disposition.
See this image and copyright information in PMC

Comment in

References

    1. De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet (London, England). 2015;385:1406–17. - PubMed
    1. Kirchhoff P, Clavien P‐A, Hahnloser D. Complications in colorectal surgery: risk factors and preventive strategies. Patient Saf Surg. 2010;4:5. - PMC - PubMed
    1. Zhang T, Yang J, Ding C, Li Y, Gu L, Wei Y, et al. Preoperative intra‐abdominal sepsis, not penetrating behavior itself, is associated with worse postoperative outcome after bowel resection for Crohn disease: a retrospective cohort study. Medicine. 2015;94:e1987. - PMC - PubMed
    1. Singh S, Al‐Darmaki A, Frolkis AD, Seow CH, Leung Y, Novak KL, et al. Postoperative mortality among patients with inflammatory bowel diseases: a systematic review and meta‐analysis of population‐based studies. Gastroenterology. 2015;149:928–37. - PubMed
    1. Gillis C, Carli F. Promoting perioperative metabolic and nutritional care. Anesthesiology. 2015;123:1455–72. - PubMed

Publication types